A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension

Exclusion Criteria

• •History of chronic pulmonary hypertension (PH), as judged by the Investigator at screening
• •Known New York Heart Association (NYHA) Functional Class III or IV symptoms
• •Left heart failure with ejection fraction (EF) \< 35%
• •Acute coronary syndrome
• •Body Mass Index (BMI) \> 45 kg/m\^2
• •Estimated glomerular filtration rate (eGFR) \< 30 mL/min
• •MetHb \> 3%
• •PCO2 \> 7
• •Indication of liver disease, defined by serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN) at screening
• •Haemoglobin \< 80 g/dL
• •Thrombocytopenia (platelet count \< 80000/mm\^3)
• •Prothrombin time International ratio (INR) \> 1.4
• •Pregnancy, or a positive pregnancy test
• •Ongoing daily treatment the last 3 days with non-steroidal anti-inflammatory drugs
• •Known active malignancy within the past 3 years
• •History of allergy/hypersensitivity to PD or ongoing allergy/hypersensitivity or history of hypersensitivity to drugs with a similar chemical structure or class to PDNO
• •History of any other clinically significant disease or disorder
• •Participation in any interventional clinical study